Ursula A. Matulonis, MD, on Ovarian Cancer: Roundup of Studies on Olaparib, Cediranib, Mirvetuximab Soravtansine, Bevacizumab, and Pembrolizumab
ASCO20 Virtual Scientific ProgramUrsula A. Matulonis, MD, of Dana-Farber Cancer Institute, discusses three important studies focusing on newer therapies for patients with recurrent platinum-sensitive, platinum-agnostic, and advanced recurrent ovarian cancers (Abstracts 6003, 6004, and 6005).
Related Videos
Scott Kopetz, MD, PhD, on Colorectal Cancer: Encorafenib Plus Cetuximab With or Without Binimetinib
Scott Kopetz, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses phase III results of the BEACON CRC study, which confirmed that, compared with standard...
Reshma Jagsi, MD, DPhil, and Narjust Duma, MD, on Diversity in Oncology: A Discussion of Evidence-Based Transformation
Reshma Jagsi, MD, DPhil, of the University of Michigan, and Narjust Duma, MD, of the University of Wisconsin Carbone Cancer Center, discuss the state of dive...
Suresh S. Ramalingam, MD, on NSCLC: Nivolumab Plus Ipilimumab vs Chemotherapy
Suresh S. Ramalingam, MD, of Emory University, discusses a 3-year update from the CheckMate 227, Part 1, trial, which showed that nivolumab plus ipilimumab continued to provi...
Peter Reichardt, MD, PhD, on GIST: Adjuvant Imatinib for High-Risk Disease
Peter Reichardt, MD, PhD, of Helios Klinikum Berlin-Buch, discusses the 10-year survival analysis of 3 years vs 1 year of adjuvant imatinib for patients with high-risk gastro...
Jeffrey A. Meyerhardt, MD, MPH, on Colon Cancer: Celecoxib and FOLFOX for Stage III Disease
Jeffrey A. Meyerhardt, MD, MPH, of Dana-Farber Cancer Institute, discusses results from the CALGB/SWOG 80702 trial of celecoxib plus standard adjuvant therapy with fluorourac...
